Clinical trialNCT07075185RecruitingPhase 1Interventional

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

SponsorKelonia Therapeutics, Inc.Enrollment70Blood Protein DisordersGene TherapyHematologic Disease and DisordersHemostatic DisordersImmune System DiseaseImmunoproliferative Disorders+8 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

the Royal Prince Alfred
Camperdown, New South Wales, Australia
Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Recruiting
the Alfred Paula Fox Melanoma and Cancer Centre
Melbourne, Victoria, Australia
Recruiting

United States

City of Hope
Duarte, California, United States
Scott Goldsmith, MD
Recruiting
Stanford University
Palo Alto, California, United States
Surbhi Sidana, MD
Recruiting
Ucsf
San Francisco, California, United States
Jodi Lipof, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Ciara Freeman, MD, MSc, PhD
Recruiting
Emory University Hospital
Atlanta, Georgia, United States
Nisha Joseph, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Noopur Raje, MD
Recruiting
Providence Portland Medical Center
Portland, Oregon, United States
Stacey Lewis, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

KLN-1010

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Jul 2025
Primary completion: 31 Mar 2027
Completion: 31 May 2042
Last update posted: 8 Jul 2026
Registered enrollment: 70
Registry id: NCT07075185

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.